{"entity":{"type":"insider","cik":"0001342894","url":"/insider/0001342894","json_url":"/insider/0001342894.json","name":"Sharp John P","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":6,"first":"2013-08-20","last":"2018-12-11","span_basis":"filed_date"},"name_variants":[{"name":"Sharp John P","source":"filing","n_filings":6,"first_seen":"2013-08-20","last_seen":"2018-12-11"}],"transactions":[{"id":6663137,"accession":"0001209191-18-061987","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-061987","line_url":"/filing/0001209191-18-061987#line-1","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (CFO and Secretary)","role_mark":"O","role_mark_label":"Officer (CFO and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO and Secretary","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.84,"price_display":"3.84","price_state":"stated","total_value":19200.0,"total_display":"19,200.00","total_whole":"19,200","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-07","filed_date":"2018-12-11","scope":"insider"},{"id":7005623,"accession":"0000886163-14-000027","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0000886163-14-000027","line_url":"/filing/0000886163-14-000027","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (VP Finance and CFO)","role_mark":"O","role_mark_label":"Officer (VP Finance and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Finance and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":86953.0,"shares_display":"86,953","price_per_share":74.74035731947144,"price_display":"74.74","price_state":"stated","total_value":6498898.29,"total_display":"6,498,898.29","total_whole":"6,498,898","shares_owned_after":17667.0,"shares_owned_after_display":"17,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-12","filed_date":"2014-02-14","scope":"insider","n_lines":12},{"id":5494503,"accession":"0000886163-13-000126","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000886163-13-000126","line_url":"/filing/0000886163-13-000126#line-2","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (VP Finance and CFO)","role_mark":"O","role_mark_label":"Officer (VP Finance and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Finance and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700.0,"shares_display":"700","price_per_share":53.44,"price_display":"53.44","price_state":"stated","total_value":37408.0,"total_display":"37,408.00","total_whole":"37,408","shares_owned_after":17667.0,"shares_owned_after_display":"17,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-12","filed_date":"2013-12-16","scope":"insider"},{"id":5313176,"accession":"0000886163-13-000122","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000886163-13-000122","line_url":"/filing/0000886163-13-000122#line-1","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (VP Finance and CFO)","role_mark":"O","role_mark_label":"Officer (VP Finance and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Finance and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":56.08,"price_display":"56.08","price_state":"stated","total_value":336480.0,"total_display":"336,480.00","total_whole":"336,480","shares_owned_after":17667.0,"shares_owned_after_display":"17,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-06","filed_date":"2013-12-09","scope":"insider"},{"id":5145105,"accession":"0000886163-13-000112","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000886163-13-000112","line_url":"/filing/0000886163-13-000112#line-2","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (VP Finance and CFO)","role_mark":"O","role_mark_label":"Officer (VP Finance and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Finance and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1123.0,"shares_display":"1,123","price_per_share":53.0,"price_display":"53.00","price_state":"stated","total_value":59519.0,"total_display":"59,519.00","total_whole":"59,519","shares_owned_after":23667.0,"shares_owned_after_display":"23,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-18","filed_date":"2013-11-20","scope":"insider"},{"id":5521170,"accession":"0000886163-13-000086","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000886163-13-000086","line_url":"/filing/0000886163-13-000086#line-2","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001342894","owner_name":"Sharp John P","owner_display_name":"Sharp John P","owner_url":"/insider/0001342894","role":"Officer (VP Finance and CFO)","role_mark":"O","role_mark_label":"Officer (VP Finance and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP Finance and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":42.7492,"price_display":"42.75","price_state":"stated","total_value":320619.0,"total_display":"320,619.00","total_whole":"320,619","shares_owned_after":24166.0,"shares_owned_after_display":"24,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-16","filed_date":"2013-08-20","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001169245","name":"PhaseBio Pharmaceuticals Inc","url":"/issuer/0001169245","role":"Officer (CFO and Secretary)","n_filings":1,"first_seen":"2018-12-11","last_seen":"2018-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000886163","name":"LIGAND PHARMACEUTICALS INC","url":"/issuer/0000886163","role":"Officer (VP Finance and CFO)","n_filings":5,"first_seen":"2013-08-20","last_seen":"2014-02-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001342894","retrieved_at":"2026-08-23T02:09:20+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}